Pacira Pharmaceuticals, Inc.
) recently reported results from a study on Exparel. The study
was conducted to evaluate Exparel as the foundation of a
multimodal postsurgical pain management regimen for patients
undergoing total knee arthroplasty (TKA). Data was presented by
Pacira at the 7th Annual Orthopedic and Spine Summit.
The study enrolled 200 patients undergoing TKA, who received
either a femoral nerve block or Exparelin 1:1 ratio. The study
showed a lower pain score of 4.0 in the Exparel group compared to
a 4.9 score in the femoral nerve block group during the first day
of surgery. During week 3 and week 9 follow up, greater
improvement in knee flexion was seen with 109° to 121° for the
Exparel group versus 100° to 105° for the femoral nerve block
Shorter overall length of hospital stay was seen in the
Exparel group (2.2 days) as compared to the femoral nerve block
group (2.5 days). This study showed a 55.5% reduction in
medication and delivery system costs. Increased satisfaction was
also found in the Exparel group.
Exparel is currently approved by the U.S. Food and Drug
Administration (FDA) for administration into the surgical site to
produce postsurgical analgesia. The drug was approved by the FDA
in the final quarter of 2011 and launched in Apr 2012. In the
second quarter of 2013, net Exparel revenues were $15.2 million,
up sequentially by 46.2%.
Pacira carries a Zacks Rank #3 (Hold). Other stocks that look
Biogen Idec Inc.
Gilead Sciences Inc.
). All three carry a Zacks Rank #1 (Strong Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
PACIRA PHARMACT (PCRX): Free Stock Analysis
To read this article on Zacks.com click here.